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There can no longer be doubt that transplantation of tissues 
and organs will be practiced with increased frequency and success in 
the future. The number of patients who have been returned to a useful 
place in society after renal homotransplantation has risen steadily since 
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heart,16, 32, 33 spleen41. 69 and pancreas27 have also recently been under-
taken. 
Progress in various areas of transplantation research has been 
summarized in several books, monographs and special issues of 
journals5, 10, 12, 38, 58, 61, 86, 87 and will not be recapitulated here, Instead, 
attention will be focused upon several specific questions that pertain to 
transplantation of the kidney and liver, but that probably also have rele-
vance to the transplantation of other organs. 
KIDNEY TRANSPLANTATION 
The Fate of the Chronically Tolerated Homograft 
Between November 1962 and March 1964,64 patients were treated 
in Denver with renal homo grafts obtained from healthy volunteers. The 
30 recipients (47 per cent) in this group who are still alive have now 
been followed for 4 to 51fa!years. 
It was evident from the beginning that the principal mortality was 
early (Fig. 1) and that a patient who survived with good homograft 
function beyond the first few postoperative months had an excellent 
chance of living for a significant although then unknown period. The 
data now available on these cases permit a much clearer projection of 
what patients treated more recently and more successfully brought 
through the early postoperative period can expect in terms of 5-year 
outlook. 
The picture has remained encouraging in cases in which intrafa-
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Figure 1. Life survival curves of 64 patients treated in Denver with renal homotrans-
plantation between November 1962 and March 1964. Preoperative histocompatibility testing 
was not done. The vertical arrows indicate the time of minimum followup. 
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milial transplantation was the original procedure. There were 46 recipi-
ents of consanguineous kidneys. Of these, 15 died within the first year, 
but only 1,1, and 1 were lost during the second, third, and fourth postop-
erative years (Fig. 1). The present survival after 4 to 51/3 years is 28 of 
46 (60.9 per cent). None of the 28 patients have received late retrans-
plantation, and none have been returned to dialysis prograrps. The 
function of these chronically tolerated homo grafts has been shown by 
Ogden33 to be generally almost as good as the contralateral kidneys left 
in their donors. 
With recipients of nonrelated homografts, the picture was not as 
good. There was a higher rate of early mortality inasmuch as 12 of the 
18 patients in the series died within the first year. Furthermore, a 
steady mortality rate continued thereafter. Two more patients died in 
the second postoperative year, as well as two others who reached 33 and 
51 months. Now only two of the original 18 recipients are alive, one by 
virtue of a second homotransplantation 2112 years after the first. The 
other patient has had continuous excellent function from his nonre-
lated homograft for more than 4 years. 
The foregoing observations in a large series of transplantations 
have made it clear that survival for several years can often be attained, 
particularly if related donors can be found. However, it can hardly be 
expected that most of these homo grafts will function for a normal 
lifetime since the presence in them of serious structural abnormalities 
is the rule rather than the exception. This conclusion was reached by 
Dr. K.A. Porter of St. Mary's Hospital and Medical School, London, on 
the basis of examination of 2-year renal biopsies obtained from all 
Denver patients who survived this long. 56. 57 
An occasional homograft was completely normal. However, in the 
others there were pathologic changes that were not always reflected in 
impairment of renal function. There were vascular lesions including 
fibrous thickening of the intima of interlobular arteries often with rup-
ture or duplication of the internal elastic lamina; deposition of a hyaline-
like substance in the subintimal layer of afferent arterioles (Fig. 2); 
and deposition of the same PAS-positive hyaline material in the glo-
merular capillaries. The last finding has been shown by Harlan et al. 18 
to often be associated with a nephrotic syndrome. 
The homo grafts with vascular lesions often had other secondary 
morphologic changes including fibrosis of the glomerular tufts, spotty 
periglomerular fibrosis, interstitial fibrosis or tubular atrophy. The ma-
jority of homografts also contained focal accumulations of mono-
nuclear cells. Ten to 40 per cent of these cells were pyroninophilic, the 
variety found in acutely rejecting homo grafts. In the chronically func-
tioning homografts, the presence of such cells was not incompatible 
with good or even normal function. 
Further studies with immunofluorescence techniques and with fer-
ritin-conjugated antisera by Porter and his associates have shed addi-
tional light on some of the foregoing changes.56 The deposits in the 
subendothelial layers of small vessels and glomerular capillaries were 
shown to contain host antibodies, particularly in the IgM class but also 
often including complement, IgG and fibrinogen. These were con-
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Figure 2. Typical arteriolar lesion in a renal homograft biopsied 1 year and 9 months 
after the original operation; the patient has had no deterioration in renal function in the 
subsequent 3 years. The lumen is indicated at the upper left. Granular hyaline material (hy) 
is deposited between the endothelium (end) and the smooth muscle (8m) of the vessel. Elec-
tromicrograph. Phosphotungstic acid (x 16,800). (By permission of Ann. Surg., 162:749, 
1965). 
sidered to represent the reaction of circulating host antibodies with an-
tigens in the capillary basement membranes of the transplanted kidney. 
In three exceptional grafts, the deposits were nodular and were 
along the subepithelial side of the glomerular capillary basement 
membranes. The authors suggested that these were caused by the 
transmission of active glomerulonephritis from the recipient to the 
homograft.56 Morphologic evidence that this sequence of events was 
possible had previously been published by O'Brien and Hume52 and Pe-
tersen et al.55 More recently, Lerner et al. 36 conclusively showed that 
anti-glomerular basement membrane (anti-GBM) antibodies present in 
the serum of a patient with active glomeruionephritis can fix to and 
adversely affect a subsequent transplanted homograft. Presumably, this 
complication could be avoided if patients with acute or subacute 
glomerulonephritis were subjected to preliminary nephrectomy, and 
transplantation were deferred until recipient serum levels of anti-GBM 
antibody disappeared. 
The possibility that many, or even most, renal homografts will grad-
ually fail is not a serious argument against further clinical transplanta-
tion. The degree of social and vocational rehabilitation in the interval of 
satisfactory kidney function is usually relatively complete. Moreover, it 
is now known chiefly as the result of Hume's work23 that retransplan-
tation for the indication of a failing first homograft can be done with 
reasonable expectation of success. This expedient was considered too 
late in some patients in our early series who died with diminishing 
renal function long after operation. 
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Histocompatibility Typing 
During the time that the first Denver series was accumulated, there 
were no practical methods of predicting the vigor or tenacity of the an-
ticipated rejection process. It was quickly recognized that red blood cell 
group incompatibilities between donors and recipients could lead to 
immediate loss of the transplanted kidneys, from which experience the 
now widely accepted rules were formulated61. 67 concerning tissue 
transfer between people of different ABO types (Table 1). Since other 
preoperative analyses of donor-recipient compatibility were not 
available, the transplantation itself became a test system in which, pre-
sumably, the recipients of biologically unfavorable kidneys were ruth-
lessly weeded out by early mortality. It was decided to retrieve the infor-
mation derived from this unacceptable situation and to use it to try to 
improve donor selection for future cases. -rhe effort involved collabo-
ration with Dr. Paul Terasaki of Los Angeles and Dr. K.A. Porter of 
London. In the meanwhile, a six month moratorium on new cases was 
declared. 
For years, Terasaki, Dausset, Payne, van Rood, Ceppellini, Amos, and 
others20 had worked with a variety of serologic techniques on the char-
acterization of the antigens contained in leukocytes. These workers were 
convinced that most antigens in renal and other tissue were also present 
in the readily accessible peripheral lymphocytes. By studying the lym-
phocytes of prospective donors and recipients, they hoped that an idea 
could be obtained of their general tissue compatibility. Unfortunately, 
there was at that time no proof that the antigen systems under investi-
gation had any relationship to histocompatibility, and it was to establish 
this point that the Denver patients were employed. 
First, Terasaki analyzed the antigenic constitution of a number of 
surviving recipients and their donors using his lymphocyte cytotoxicity 
test. The quality of the matches was graded and compared with clinical 
rankings accorded by those caring for the patients. The correlation was 
imperfect. It was evident that many patients had retained good ho-
mograft function for long periods in spite of what appeared to be poor 
matches with their donors. Nevertheless, most of the really superior 
clinical results were in patients who had received exceptionally well 
matched kidneys.70, 81 Later, a far more striking correlation was found 
between the Terasaki results and the degree of histologic injury noted 
by Porter in the two year biopsies mentioned in the preceding section. 57 
Subsequent reports from other centers have supported the view that lym-
phocyte antigen determination is an incomplete but potentially useful 
way of assessing histocompatibility.7. 34. 54, 59, 74, 80, 83 
Table 1. Direction of Acceptable Mismatched Tissue Transfer* 
o to non-O 
RH-toRH+ 
RH+toRH-
A to non-A 
B to non-B 
AB to non-AB 
*0 is universal donor; AB is universal recipient. 
Safe 
Safe 
Relatively safe 
Dangerous 
Dangerous 
Dangerous 
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Figure 3. Survival of 42 patients treated with renal homotransplantation between 
October 1964 and April 1966. An attempt was made by Terasaki to select the most com-
patible donor among available volunteers. See text for discussion of results. 
Although much of the previously cited support for the validity of 
antigen typing was not available in 1964, there was enough favorable 
evidence to warrant a prospective clinical evaluation. When transplan-
tation was resumed in October of that year, an effort was made by 
Terasaki to find the best possible donor among the volunteers available 
for each patient. 
The selectivity was severely limited in most cases of intrafamilial 
transplantation. In most instances, only one or two blood relatives were 
willing to donate or were acceptable on general medical or psychiatric 
grounds. Consequently, the matching was not improved to a statisti-
cally significant degree over that which could have been achieved with 
random intrafamilial pairing.78 It was not, therefore, surprising to find 
that the life survival curve in these related cases (Fig. 3) was almost 
identical to that defined in the earlier Series I. Of 25 reCipients, 16 (64 
per cent) were still alive at one year. Two more subsequently died after 
26 and 30 months, leaving a residual group of 14 (56 per cent) with a 
followup of 23 months to 3V2 years. 
In the 17 nonrelated homotransplantations, the donors were picked 
from a pool of as many as 80 volunteers. Perfect matches could not be 
found, but the quality of the pairing was improved over that which 
could have been expected by chance.78 The recipients fared better than 
those previously observed in Series I. Nine (52.9 per cent) of the 17 re-
cipients were still alive at the end of the first year (Fig. 3). Three more 
patients were lost at 18,27 and 35 months respectively, but in two there 
was life-sustaining renal function until death. Six of the 17 patients 
(35.3 per cent) are still living with good to excellent function of their 
original homo grafts 28 to 40 months after transplantation. The mean 
creatinine clearance in the remaining group is 83.4 ± 26.2 (SD) ml./min. 
In both related and nonrelated cases, observations were similar to 
those made retrospectively in Series I. Several recipients of poorly 
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matched kidneys fared surprisingly well. A few patients with good 
matches experienced vigorous and prolonged rejection. The prepon-
derance of the best results, however, were in patients with close anti-
gen matches with their donors. 
The failure to improve survival in the related transplantations or to 
increase it more in the nonrelated cases was a keen disappointment since 
evidence from many investigators now suggested more strongly than 
ever that the tissue typing being used provided a measure of histocom-
patibility.7. 34.54.59.74.80.83 It seemed that safer methods of immunosup-
pression would be required before histocompatibility typing could re-
ceive a fair trial. This point was particularly well illustrated by an ex-
periment carried out in our laboratories by Dr. Thomas L. Marchioro. 
He performed autotransplantation in 18 dogs. Postoperatively, the ani-
mals were given immunosuppressive therapy just as if they had re-
ceived homografts. Despite the absence of an immunologic barrier, the 
life survival curve of the recipients was similar to that described previ-
ously after human renal homotransplantation. There was an early high 
mortality rate and a later occasional death (Fig. 4); after 1 year, less 
than half the animals were still alive. Most deaths were caused by in-
fectious disease complications. 
It has been recognized for several years that many and possibly 
most deaths after clinical homotransplantation are due to drug toxicity. 
At the beginning, bone marrow depression from overdoses of azathio-
prine was common, but with increased experience this complication is 
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Figure 4. Survival of 18 dogs receiving renal autotransplantation followed by post-
operative therapy with azathioprine. the drug doses were similar to those used after ex-
perimental renal homotransplantation. There was a high early mortality and an occasional 
late death. Most of the deaths were the result of infectious complications. Less than half of 
the animals were alive at 1 year. Note the similarity of the survival curves to those shown 
in Figures 1 and 3. 
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Figure 5. Course of a 37-year-old man (LD 47) who received a kidney from his younger 
brother. Both were A+ blood type. Note the severe late rejection after 9 months and the 
subsequent slow deterioration of renal function. The late thymectomy did not either induce 
lymphopenia or make the subsequent management easier; the post-thymectomy changes in 
lymphocyte counts were related to adjustments in steroid dosage. (By permission of Ann. N.Y. 
Acad. Sci., 129:605, 1966). 
now rarely seen. Avoidance of the hazards of the steroid therapy that is 
usually combined with azathioprine has not been so simple. In many 
cases, continued function of a homograft is dependent upon continua-
tion of unacceptably large quantities of prednisone for long periods. 
The complications that follow are exceedingly troublesome at best and 
lethal at worst. These include cosmetic deformity, bone deminerali-
zation often with spontaneous fractures, muscle wasting, arrest of 
growth in infants, fatty infiltration of the liver, pancreatitis, and gastro-
intestinal ulceration and hemorrhage. Most serious, however, is the con-
sequent susceptibility to microorganisms of all types. 
If the resultant infections are due to common pathogenic bacteria 
they can be treated effectively with properly chosen antibiotics. Very 
often, however, these are caused by fungi, protozoa or viruses for which 
specific therapy is not available. The tragic consequences are illus-
trated in Figure 5. This patient, who received a homograft from his 
brother, had an early rejection crisis followed by excellent renal 
function for the next 9 months. After the dose of prednisone was re-
duced to 10 mg./day, he had a delayed rejection, which was controlled 
by increasing the prednisone dose to a level from which subsequent 
withdrawals were not possible without further deterioration of kidney 
function. He died 15 months later but not primarily from renal failure. 
He had fatty infiltration of the liver, a duodenal ulcer and pancreatitis. 
There were cytomegalic inclusion viruses in the lungs and liver and 
diffuse pneumonitis due to Pneumocystis carinii and Aspergillus fumi-
gatus. 
Improvements in Immunosuppression 
For the aforementioned reasons, intensive efforts have been made 
in a number of laboratories to develop new and safer immunosup-
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pressive agents. The most encouraging results have been with het-· 
erologous antilymphocyte serum (ALS) and its globulin derivative 
(ALG). These biologic agents were first evaluated in animals by Waks-
man et al. 8 and Woodruff and Anderson95 for their ability to prevent 
rejection. Notable contributions have since been made by Monaco and 
Russell and their collaborators/3• 47. 48 Levey and Medawar and many 
others. 
In our laboratory, the horse has been used as the source of immune 
serum. 22• 68 After immunization with the lymphoid tissue of the species 
to be eventually treated (Fig. 6), the horses are bled and the serum is 
separated. Undesirable anti-red cell and anti-plasma protein antibodies 
are absorbed with donor species red cells and plasma or serum. The anti-
lymphocyte antibodies in the IgG fraction of the horse serum can then 
be removed with several techniques. Initially, we employed ammonium 
sulphate precipitation for crude globulin extraction, but more recently 
pure IgG has been removed in bulk quantities by batch mixing with 
DEAE cellulose. The ALG can then be given by intramuscular injection. 
The guidelines for the clinical use of heterologous ALG were pro-
vided by extensive investigations in dogs. The ability of the antidog-
lymphocyte globulin to mitigate homograft rejection was easily and 
unequivocally demonstrated.66• 68 Nevertheless, protection was incom-
plete. In about a fourth of the animals, rejection proceeded as might 
have been expected in untreated animals. Its onset was delayed or occa-
LYMPH 
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Figure 6. Schematic representation of the preparation of antilymphocyte globulin 
(ALG). The most convenient source of lymphocytes is the cadaver spleen. An adjuvant is 
not used for the horse immunization. There are several methods of globulin extraction as 
discussed in the text. The desired equine antibodies are thought to be in the IgG (7S) fraction 
of the horse serum. 
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Figure 7. The course of a patient who received antilymphocyte globulin (ALG) before 
and for the first 4 months after renal homotransplantation. The donor was an older brother. 
The Terasaki match was a good one. There was no early rejection. Prednisone therapy was 
started 40 days postoperatively because of the high rises in the serologic titers, which in-
dicated a host response against the injected foreign protein and which warned against a pos-
sible anaphylactic reaction. Note the insidious onset of late rejection after cessation of 
globulin therapy. This was treated by increasing the maintenance dose of steroids. This 
delayed complication was seen in only 2 of the original 20 patients whose survival is shown 
in Figure 8. (By permission of Surg. Gynec. Obstet.). 
sionally prevented in the rest of the animals. However, survival of as 
long as 4, 8 or 12 months was observed in the minority of recipients of 
kidneys or livers. This spectrum of results was similar to that which 
can be obtained in dogs with other potent immunosuppressive agents 
such as azathioprine. 
Other factors concerned with the toxicity of ALG influenced the 
therapeutic program finally adopted.24, 64, 68, 73 After long-term adminis-
tration of ALG, the animals usually developed antibodies against the 
injected horse protein. Many of these dogs ultimately had microscopic 
renal lesions that consisted of deposits of horse protein, with host 
gamma globulin and complement; the findings were characteristic of 
serum sickness nephritis. 24 
For these reasons it was decided to use ALG only as an adjunct to 
the standard immunosuppressive agents azathioprine and prednisone. 
The regimen ordinarily followed is shown in Figure 7. ALG was started 
a few days in advance of transplantation and continued daily for the 
first 10 to 14 postoperative days, then every other day for 2 weeks, twice 
a week for 2 months and once a week for a final month. 
The first patient was treated in this way in June 1966. From then 
until the following December, 19 patients were added to the series. One 
patient died during the second postoperative month as the direct conse-
quence of a technical surgical accident. The others are alive with good 
renal function from their original homografts 15 to 21 months later for 
a current survival of 95 per cent. 
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All these ALG-treated recipients received kidneys from blood rela-
tives. The results are shown graphically in Figure 8 and compared with 
those obtained in previous intrafamilial transplantations in our institu-
tions. For the latter purpose the consanguineous transplantations in the 
original Series I were divided into 2 consecutive groups, now termed 
Series IA and IB, to evaluate the effect of increased experience upon 
results. The intrafamilial homotransplantations described in the pre-
vious section on histocompatibility typing were Series II. In each of the 
consecutive earlier series the mortality rate in comparable followup in-
tervals had been 28 to 31 per cent. 
The probable explanation for the improved results in the ALG-
treated patients is shown in Figure 9. During the time that the se-
quential earlier series were being accumulated, there was a progressive 
tendency to use smaller doses of azathioprine both during the first four 
and the subsequent six postoperative months. This trend continued into 
the ALG series. As the average doses of azathioprine were cut, however, 
compensatory increases in the quantities of prednisone were necessary 
to maintain a somewhat poorer quality of renal function (Fig. 9, middle 
and right). The result of the slowly evolving adjustments in policy was 
a change in the causes of death as described from our institutions by 
Hill et al. 19 The early mortality from bone marrow depression and pyo-
genic infections was replaced by a delayed mortality, which was 
usually due to untreatable infections caused by unusual opportunistic 
microorganisms. 
The situation was drastically reversed in the ALG-treated patients 
in that the average daily quantities of prednisone could be sharply 
lowered during the first 4 postoperative months when ALG was being 
given. Furthermore, the steroid doses remained at acceptably low levels 
in the next 6 months after the ALG had been stopped. The ability to 
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Figure 8. Survival curve of the first 20 patients treated with antilymphocyte globulin 
(ALG) compared to that in 3 previous series of consanguineous transplantations at our in-
stitutions. Follow-ups in the globulin-treated group are 15 to 21 months. The numbers in the 
upper curve indicate the patients at risk for each monthly interval. 
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Figure 9. The average azathioprine and prednisone doses per kg. per day and the 
creatinine clearances for the first 16 postoperative weeks (shaded) and for the subsequent 
6 months (solid). Shown are the retrospective control series (Groups lA, lB and 2) and the 
ALG series (Group 3). Inclusion in the analysis was contingent upon survival for 294 days, a 
condition which was met with the highest regularity in the ALG patients. 
reduce the stringency of therapy with both azathioprine and prednisone 
was not at the expense of loss of renal function since all measures of 
renal function in the ALG-treated patients were at least as adequate as 
in the earlier series (Fig. 9, right). 
The extremely favorable results of using ALG as compared to 
earlier series occurred in spite of a sharp bias introduced by the method 
of analysis. Inclusion of any case in the studies shown in Figure 9 was 
contingent upon survival for 10 months. A substantial number of the 
most seriously ill patients in each of the retrospective series were 
thereby eliminated by their death. Inasmuch as only 1 of the 20 patients 
in the ALG group was similarly excluded, the latter series was much 
less selective. 
This experience with ALG suggests that its use as an immunosup-
pressive agent has improved the management of patients after trans-
plantation. There have been a number of side effects, however, which 
were recently summarized by Kashiwagi et al.26 Sensitization to the re-
peatedly injected horse protein has in time led to skin rashes. Fever and 
pain at the injection sites were invariable. In nearly 2 per cent of cases 
an anaphylactic reaction occurred during the course of therapy. The 
most serious adverse effects usually were observed when titers of host 
precipitating antibodies had reached high levels. Interestingly, the 
easily detectable antibodies were directed against the alpha and beta 
globulins that were present in small quantities in the ALG; only rarely 
were precipitins found against the equine gamma G globulin that is 
thought to be the biologically active part of ALG. Consequently, there is 
reason to hope that the pure gamma G globulin (IgG) that is now being 
produced in bulk as discussed earlier will eliminate some of the unde-
sirable features of ALG. 
One of the most disquieting possibilities with the clinical use of het-
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erologous ALG was that the renal homografts would become the site of 
serum sickness or direct nephrotoxic Masugi-like nephritis. This fear 
has been largely dispelled. The first eight patients treated with ALG 
received homograft biopsies at the end of their 4-month course of 
therapy. The specimens were studied with immunofluorescence and 
ferritin-labeled antibody techniques. 73 There was no trace of horse 
protein. Since then four more kidneys have been studied. In only one 
was there detectable horse protein, and in that patient there has been 
no clinical or biochemical evidence of serum sickness nephritis. 
Thymectomy in Clinical Transplantation 
In adult mice, rats and hamsters complete thymectomy causes a 
slowly developing loss in immunologic reactivity in otherwise unaltered 
animals.44• 46. 60. 76 The process can be accelerated in skin homotrans-
plantation experiments if immunosuppressive therapy is given with 
either total body irradiation9• 45 or antilymphocyte serum.25• 47 
Shortly after the appearance of the first of the above reports eight 
patients were subjected to thymectomy at our institutions 14 to 85 days 
before renal homotransplantation. Four patients died within a few weeks 
or months after receipt of their homografts. The other four are still alive 
more than 5 years later, all with excellent renal function. They are now 
four of the longest surviving recipients of renal homo grafts in the world. 
As has been previously stressed/o. 71 the role of thymectomy in the 
attainment of long-term graft function in these cases was essentially 
unanalyzable. In order to clarify this issue, a formal study of the effect 
of thymectomy was carried out in 46 more patients who were treated 
with renal homotransplantation between October 1964 and June 1966. 
All kidneys were provided by living donors of whom 37 per cent were 
unrelated. A decision for or against thymectomy was made on the basis 
of random selection from appropriately marked cards. The spectrum of 
histocompatibility typing as well as a number of other variables proved 
to be almost identical in the 22 control cases as compared to the 24 
cases in which transthoracic thymectomy was carried out before 
transplantation. 
The duration of followup for these cases is now 21 to 41 months. 
The results were assessed on the basis of early and late mortality, the 
dosages of immunosuppressive drugs necessary to retain stable ho-
mograft function and the quality of both early and late renal function. 
There were not statistically significant differences between the thy-
mectomized and non thymectomized groups in these respects. In all 46 
cases samples of the transplanted kidneys are now available for exami-
nation as a result of either autopsy or late biopsy. The histopathologic 
examination has not yet revealed clear differences between the test and 
control series of kidneys, although the specimens are currently being 
reviewed for possible subtle differentiating features. 
At the moment, however, it can be concluded that an important 
benefit did not derive from thymectomy. This does not, of course, prove 
that the thymus has no immunologic function in adult man. At the 
least, however, it does indicate that other factors are so much more 
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important in determining survival and homograft function that the loss 
of the thymus resulted in no detectable changes under the experimental 
conditions that existed from 1964 to 1966. Conceivably, future improve-
ments in management might permit unmasking of an unrecognizable 
subtle effect of thymectomy but, at present, there seems to be no justifi-
cation for the continued use of the precedure in clinical organ trans-
plantation. 
Hyperacute Rejection 
As mentioned earlier, it was soon learned that renal homografts have 
had a significant risk of being immediately destroyed if the donors and 
recipients have different ABO red cell groups in the combinations 
shown in Table 1. A rational explanation was available since the isoag-
glutinogens that allow red cells to be typed are also found in other 
tissues including the kidney.22, 75 Thus, if the kidney of an A or B donor 
were placed in a patient of a blood type, the naturally occurring anti-A 
and anti-B isoagglutinins respectively in the serum of the recipient 
could be expected to bind with the renal red cell antigens; serologic 
studies by Wilson and Kirkpatrick provide strong evidence that this ac-
tually occurs.92 
In cases in which the homografts were immediately lost, the se-
quence was typical. After the renal vessels were opened the kidney 
cortex was not well vascularized although the medulla, pelvis and 
ureter apparently had a good blood supply. These soft and cyanotic 
kidneys, which were removed within a few hours, had histologic evi-
dence of widespread small vessel thrombosis.61 A frank red cell group 
mismatch did not always lead to this kind of accident. One patient has 
normal renal function more than 5 years after transplantation under 
such circumstances. 
Recently, there have been reports of similar catastrophes in cases 
in which there was conformity of red cell types. The first case was de-
scribed briefly by Terasaki,77 and others were added by Kissmeyer-
Nielsen/I Williams89. 9o and Terasaki.79 In the serum of many of these 
patients preformed antibodies were present preoperatively that reacted 
against donor white cells. This has resulted in speculation that such 
antibodies were directly responsible for the homograft destruction by 
virtue of a high-grade nephrotoxicity.31. 89 Our own studies on hyper-
acute rejection in the absence of red cell mismatching, carried out in 
collaboration with Richard Lerner and Frank Dixon of La Jolla, Cali-
fornia, have led us to a different conclusion.6.; In five kidneys that sus-
tained rejection on the operating table there was unequivocal evidence 
of a generalized Shwartzman reaction. With immunofluorescence tech-
niques, Lerner and Dixon found massive fibrin deposition in the small 
vessels and glomerular capillaries and consequent cortical necrosis 
exactly as in an experimentally induced Shwartzman reaction. Little or 
no immunoglobulin deposition was detectable by immunofluores-
cence,65 although eluates of some of the kidneys were later shown by 
Dr. Felix Milgrom of Buffalo to contain leukoagglutinins. In three of 
the five instances, the kidney donors had been shown by Terasaki to 
have a good histocompatibility match with the recipients. 
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The generalized Shwartzman reaction was first described in 1934, 
but its significance, as summarized by Lee and Stetson35 and Hjort and 
Rapaport,21 was not understood until the last decade. Classically, it is 
produced in rabbits by two injections of endotoxin at 24-hour intervals. 
A generalized coagulopathy is produced. If the animal's reticuloen-
dothelial system (RES) can clear the breakdown products of fibrinogen 
rapidly enough, the kidney is spared from injury. If not, it becomes a 
primary target because the specific qualities of the renal microcircu-
lation make it an exceptionally good fibrin filter. The result is cortical 
devascularization and necrosis. 
A number of factors besides endotoxin can condition or precipitate 
a Shwartzman reaction, including antigen-antibody reactions; injection 
of thorotrast, carbon black, or steroids; or administration of an oxidized 
lipid diet. Their effects are incompletely understood, but presumably 
they could be influential either by reinforcing the coagulopathy and/or 
reducing the efficiency of RES function, or by suppressing counter-
regulatory fibrinolysis. 
The recipient of a renal homograft could be expected to be a good 
candidate for a Shwartzman reaction. Before operation, he undergoes 
multiple hemodialyses with attendant risks from accidental exposure to 
endotoxin in the extracorporeal circuit,28 from an additional RES load 
imposed by increased blood hemolysis4 and from the rapid changes in 
coagulation that occur with this procedure.84 With multiple blood 
transfusions, there is an increased chance that he will develop anti-
bodies against antigens in infused white blood cells or red cell sub-
groups, and that these will later react with the same antigens in the 
homograft. The operation itself introduces the latter possibility as well 
as that of a spectrum of other potential triggering antigen-antibody 
reactions either within or outside the freshly transplanted kidney. 
Steroids, which can potentiate a Shwartzman reaction by causing RES 
paralysis,82 are commonly used during and after the operation. 
Recognition that many, and possibly most, rejections on the 
operating table are due to Shwartzman reactions has practical implica-
tions. Prophylactic measures can be taken. Greater attention can be 
paid to the details of hemodialysis, including asepsis and hemolysis 
rates. The value of white cell free blood for transfusion is obvious. 
Immunologic tests to detect presensitization are available; when such 
an examination is positive in a prospective recipient, the hazards are 
predictably increased.79. 89 Under these circumstances, it may be advisa-
ble to use total body heparinization at the time of transplantation. 
This was done in 2 of our patients whose previously placed kidney 
transplants had been immediately destroyed; the final homo grafts 
functioned well.65 Once a Shwartzman reaction has started, a combi-
nation of heparin and fibrinolysin therapy might be worth a trial. 
It is probable that most and perhaps even all Shwartzman reactions 
are ultimately triggered by antigen-antibody unions at the time of 
transplantation. If these are intrarenal, they may be inherently benign 
or even undetectable with immunofluorescence studies as in our cases 
and of significance only by virtue of the devastating secondary effects 
that they can initiate depending upon a variety of other conditions. If, as 
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is now thought, the site of the immunologic reaction is not critical to 
the chain of events, it is conceivable that the Shwartzman reaction may 
lead to destruction of the kidneys after transplantation of other organs. 
Cadaveric Transplantation 
A cadaveric renal homograft was first transplanted in Denver in 
April 1963. This recipient, as well as the next two, died within 39 days. 
The kidneys functioned either poorly or not at all. No more cadaveric 
transplantations were performed for more than 2 years. 
The program was reopened in November 1965. From then until July 
1967, 12 patients received the kidney of a blood group compatible Ca-
daver as their primary homograft. In each case, a minimal followup of 
eight months is available. 
Six of these 12 recipients died after 13, 10,8, 31f2, 31f2 and 3 months. 
The other six are still alive after 27, 24, 15, 10,9 and 8 months. One of 
the latter patients, however, required transplant nephrectomy and 
regrafting one year after receipt of his first kidney; another lost his 
homograft after a year and is now anephric 15 months post-transplan-
tation. 
The last six patients in this series received ALG therapy for the first 
several postoperative months. In all cases, the donor-recipient histo-
compatibility matches as determined by Terasaki were poor. Two of the 
recipients who had received kidneys from a common cadaveric donor 
died within a one day interval more than 3 months postoperatively. 
Death was caused by pulmonary emboli. The homo grafts had little or 
no evidence of rejection. 
The other four patients, including one with preformed lymphocyto-
toxic antibodies, had good or excellent renal function during the 4-
month period of ALG therapy. After its discontinuance, all have had 
evidence of slow but progressive rejection. 
Other groups with much more extensive experience in cadaveric 
transplantation have repeatedly expressed optimism about the future of 
this approach.6, 12, 23, 29, 30, 39 It is a point of view with which few would 
disagree, especially since the prospects of transplanting livers, lungs 
and hearts will depend upon the use of cadaveric organs. Nevertheless, 
it is worth emphasizing that the costs in mortality, morbidity and rehos-
pitalization have been high in all centers. Furthermore, survival ex-
ceeding 4 years with continuous function of nonrelated renal ho-
mografts is rare. To our knowledge there are only four patients whose 
courses have been this long-one of Dr. Willard Goodwin who was 
treated at UCLA in June 1963, another who has been followed by Dr. 
David Hume of Richmond since August of that year and two more who 
were in our Series I. 
LIVER TRANSPLANTATION 
The first clinical liver transplantations were performed in 1963.72 In 
these cases, the recipients' diseased livers were removed and replaced 
with cadaveric homografts (orthotopic transplantation). By the summer 
of 1967, there had been nine such attempts-seven in Denver62• 72 and 
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one each in Boston49 and ParisY The survival had been from 0 to 23 
days. 
Since then, six new trials have been made at our institutions with 
more encouraging results. All recipients survived for at least one post-
operative month, and four are still alive after 1, 31J2, 6 and 71/2 months; 
the other two patients died after 2 and 41J2 months. The improved re-
sults were the product of several improvements in care as reported else-
where.63 
First, an efficient technique of preservation had been developed in 
dogs, which permitted livers to be stored for 8 to 24 hours and then suc-
cessfully transplanted as orthotopic homografts. 2 The method that com-
bined hypothermia, low flow perfusion with diluted blood, and hyper-
baric oxygenation was used in the clinical cases for several hours after 
death of the donors and until the recipients could be prepared. Good 
immediate hepatic function was obtained in each case (Fig. 10). 
In each of these cases, the compatibility of the donor and recipient 
white cell antigens was studied in advance of operation. A good match 
with compatibility in all six currently recognized components of the re-
cently defined HLA systemBO was present in only one case. In three, 
there were breaches in one major antigen group, and in the other two 
there were mismatches in two of the six groups. 
BLOOD CULTURE 
4 
40 
TEMPERATURE 3" 
1 
~ 
PT. J. R. 10.8 kg 
(·C) 38 
PTt1----~r-----~----~_1~~~~~~----------~~ 
SGOT (I.U.) 
SGPT (I.u.) 
BILIRUBIN 
3. 
1200 
800 
400 
(mg per 100 mil 4 
TMAL--- Ofm~~~~~~~~~~~==~~~~~=-~ __ ~~~= CONJUGATED _ _ _ _ _ 0 
8 
TOTAL PROTEIN - • 
ALBUMIN --_.-
Y GLOBULIN ... _ ... 
(mg per 100 mil 
AZATHIOPRINE 30 20 (mg) 10 0 
PREDNISONE 10 20 (mg) 30 40 
50 
ALG 
TIME IN DAYS 
Figure 10. Course of a 1 '{.-year-old girl who was treated with orthotopic hepatic homo-
transplantation. The indication for the operation was a hepatoma. Note the essentially stable 
liver function except at the times of septic liver infarctions which were treated with debride-
ment. The septicemia, indicated by encircled crosses, was with various gram-negative rods or 
candida albicans. The thoracotomy was for an unexpanded right upper lobe. The laparotomy 
was for excision of a tumor recurrence. 
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Figure 11. Liver scan per-
formed 1 month after hepatic 
homotransplantation in the 1'/2-
year-old patient whose course is 
depicted in Figure 10. Antero-
posterior as well as lateral views 
show large defect (arrows). Ex-
ploration revealed a septic infarct 
in the homograft. 
In all cases, a conservative attitude toward immunosuppression 
was taken during the early postoperative period, particularly in the 
dosages of azathioprine (Fig. 10). Large initial doses of prednisone were 
given but rapidly reduced. Finally, heterologous ALG was administered 
in a course similar to that described earlier after renal homotransplan-
tation (Fig. 10). 
The six recipients were all infants. The indication for operation was 
a hepatoma in the first patient and extrahepatic biliary atresia in the 
other five. In all but one case, the early convalescence was remarkably 
rapid. Pre-existing jaundice was quickly cleared. Eating was begun on 
the second to fourth postoperative days. 
A specific life-threatening complication was encountered in all but 
the last two patients. From 2 days to 2 months postoperatively, sep-
ticemia with gram-negative microorganisms interrupted recovery. This 
was accompanied by large increases in SGOT and SGPT (Fig. 10), and 
eventually septic infarctions within the liver were found. Liver scans 
showed filling defects that were usually in the posterior-superior por-
tions of the right lobe (Fig. 11). 
In one case, the development of hepatic sepsis was not surprising 
inasmuch as a serious technical accident could be implicated. The ho-
mograft had a double arterial supply and the two vessels were anasto-
mosed to the terminal right and left branches of the recipient hepatic 
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artery. The artery to the right lobe thrombosed on the second postop-
erative day, eventually necessitating a partial right lobectomy. In the 
three other children the complication occurred after a benign early post-
operative course, and there was no obvious mechanical explanation. 
The unusual susceptibility of the transplanted liver to invasion by 
enteric organisms is not surprising in view of its perfusion by splanch-
nic venous blood, as well as the necessity for connecting its biliary 
drainage system to the intestinal tract. The precise events of pathogene-
sis, however, can only be speculated upon in individual cases. In a 
recent analysis of the problem in dogs,3 any factor that caused liver 
necrosis, including the injury of rejection, was shown to predispose to 
liver abscess formation. It is thought that, in at least some clinical 
cases, the intensity of immunosuppression may have been inadequate, 
that the infarctions were a manifestation of rejection, and that the bac-
terial invasion was a secondary event. 
Once established in the clinical cases, the infected liver infarcts 
required aggressive therapy. Debridement and drainage were carried 
out through lateral incisions in the right tenth intercostal space, taking 
care to enter neither the chest nor the abdomen. These local measures 
plus therapy with properly chosen antibiotics have tided two patients 
over the crisis, but two others with septic liver infarctions eventually 
died. 
An alternative to orthotopic liver transplantation has also been 
given a clinical trial, namely transplantation of an auxiliary organ. 
Only five cases have been reported,!' 8. 14 but it is known that many more 
have been attempted. The longest survival after auxiliary liver trans-
plantation has been 34 days.14 Analyses of the special physiologic and 
technical difficulties with this approach have been published,42 suggest-
ing that it may be a less desirable procedure than the orthotopic opera-
tion. 
SUMMARY 
Several separate issues in organ transplantation have been re-
viewed, based upon our own experience with renal and liver transplan-
tation. The topics surveyed include projections of survival after renal 
homotransplantation in the past and today, the role of histocompati-
bility typing, improvements in immunosuppression, an evaluation of 
thymectomy and the contribution of the Shwartzman reaction to hyper-
acute rejection. In addition, a speCific problem of hepatic sepsis after 
liver transplantation has been described. 
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